RWA-USA-1 LLC has filed an amendment to its offering statement, revealing a total offering amount of $18 million. This amendment, filed on October 29, 2026, is significant as it highlights the company's ongoing efforts to secure funding in the competitive residential sector.
RWA-USA-1 LLC, incorporated in Delaware, is a limited liability company based in Visalia, California. The company operates within the residential industry, focusing on attracting investments to support its growth initiatives. The recent filings indicate that RWA has not yet sold any securities, with the total amount remaining at $18 million.
The filing states, "The total remaining is $18 million," emphasizing that the company is still in the process of seeking investors. The amendment also notes that the minimum investment accepted is set at $10,000, making it accessible for a range of potential investors.
This offering is particularly notable as it involves a projected sales commission of approximately $360,000, which is considered an estimate. The proceeds from this offering are earmarked for management fees and reimbursement of reasonable expenses, as outlined in the filing.
The amendment may impact various stakeholders, including potential investors looking for opportunities in the residential market. The filing indicates that there are no non-accredited investors involved at this stage, which aligns with the company's focus on attracting qualified investors.
Looking ahead, the filing does not specify what steps RWA-USA-1 LLC will take next, leaving the future of this offering open-ended. The company’s strategy to raise funds may influence its operations and competitive position within the residential sector.
Read Next
Workers United Files to Sell $8.4 Million in Amalgamated Stock
Carvana Co. files to sell 10 million shares of stock
Platford Giles Richard to Sell 55,617 Takeda Shares
Takeda's Teresa Bitetti to Sell 46,609 Shares Amid Tax Obligations
Kiniksa Pharmaceuticals reports significant stock sale by officer
Moat Ross to Sell Over 103,000 Shares of Kiniksa Pharmaceuticals










